GoodRx Holdings (GDRX) Long-Term Deferred Tax (2019 - 2026)

GoodRx Holdings' Long-Term Deferred Tax history runs 7 years deep, the most recent figure standing at $53.0 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 31.28% year-over-year to $53.0 million; the TTM figure through Mar 2026 stood at $53.0 million (down 31.28% YoY), while the FY2025 annual figure was $57.1 million, down 26.0% from the prior year.
• Long-Term Deferred Tax came in at $53.0 million for Q1 2026 at GoodRx Holdings, down from $57.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $77.2 million in Q4 2024 to a low of $53.0 million in Q1 2026.
• A 4-year average of $66.1 million and a median of $65.3 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax advanced 18.25% in 2024 and sank 31.28% in 2026, its largest moves.
• GoodRx Holdings' Long-Term Deferred Tax stood at $65.3 million in 2023, then rose by 18.25% to $77.2 million in 2024, then retreated by 26.0% to $57.1 million in 2025, then fell by 7.12% to $53.0 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $53.0 million, $57.1 million, and $69.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison